Background: Early-stage breast cancer is among the most prevalent and costly malignancies treated in the American health care system. Adjuvant radiotherapy after lumpectomy represents a substantial portion of breast cancer expenditures. The relative value of novel radiotherapeutic approaches such as intraoperative radiotherapy (IORT) and hypofractionated whole breast irradiation (HF-WBI) compared with conventionally fractionated whole breast irradiation (CF-WBI) is unknown. Therefore, we used prospectively collected outcomes from randomized clinical trials (RCTs) to compare the costeffectiveness of these approaches. Methods: We constructed a decision-analytic model that followed women who were treated with lumpectomy for early-stage breast cancer. Recurrence, mortality, complication rates, and utilities (five-year radiation-associated quality of life scores), were extracted from RCTs. Costs were based on Medicare reimbursement rates. Cost-effectiveness from societal and health care sector perspectives was estimated considering two scenarios-the first assumes that radiation-associated disutility persists five years after treatment, and the second assumes that disutility discontinues. Lifetime outcomes were summarized using incremental cost-effectiveness ratios (ICERs). Deterministic and probabilistic sensitivity analyses evaluated the robustness of the results. Results: HF-WBI dominated CF-WBI (ie, resulted in higher quality-adjusted life-years [QALYs] and lower cost) in all scenarios. HF-WBI also had a greater likelihood of cost-effectiveness compared with IORT; under a societal perspective that assumes that radiation-associated disutility persists, HF-WBI results in an ICER of $17 024 per QALY compared with IORT with a probability of cost-effectiveness of 80% at the $100 000 per QALY willingness-to-pay threshold. If radiation-associated disutility is assumed to discontinue, the ICER is lower ($11 461/QALY), resulting in an even higher (83%) probability of relative costeffectiveness. The ICER was most sensitive to the probability of metastasis and treatment cost. Conclusions: For women with early-stage breast cancer requiring adjuvant radiotherapy, HF-WBI is cost-effective compared with CF-WBI and IORT.
with early-stage disease, for which adjuvant radiotherapy following lumpectomy or breast conserving surgery (BCS) is a major contributor to treatment costs (5) .
Conventionally fractionated whole breast irradiation (CF-WBI) involves a daily treatment schedule lasting five to seven weeks and has been mainstay of adjuvant radiation in the United States. Two newer radiotherapy techniques hold promise for reducing treatment time, lowering costs, and improving quality of life. The first, hypofractionated whole breast irradiation (HF-WBI), is an alternative form of externally delivered whole breast treatment that utilizes approximately 15 to 20 sessions (three to four weeks) of daily treatments. HF-WBI has been shown in several randomized trials to be equally efficacious and less toxic than CF-WBI for nearly all patients with early-stage breast cancer (6, 7) . However, the uptake of HF-WBI among women receiving BCS remains low (8) .
The second alternative to CF-WBI is intraoperative radiotherapy (IORT), which entails treating the breast tissue around the tumor cavity in a single treatment session, which occurs during the lumpectomy procedure itself (9) (10) (11) (12) (13) . The efficacy of this technique has been evaluated in two recently published randomized trials-the Electron Intraoperative Radiotherapy Trial (ELIOT) and the TARGeted Intraoperative Radiotherapy Trial (TARGIT-A) (11, 12) . IORT is especially compelling as a way to improve access among patients for whom external radiation is burdensome, such as those who cannot travel long distances to radiation facilities and those with advanced age or poor socioeconomic status (14) (15) (16) . However, IORT is associated with modestly worse local control outcomes than CF-WBI, which over the long term may alter differences in quality of life and costs of care.
The wealth of clinical trial data comparing conventional and newer forms of radiotherapy provides a critical opportunity to compare the relative value proposition of these approaches. To that end, we utilized data collected from randomized trials in combination with decision-analytic methods to perform a rigorous value-based comparative cost-effectiveness analysis of IORT, HF-WBI, and CF-WBI.
Methods

Model Overview and Baseline Cohort
We constructed a Markov-based state transition model to simulate the clinical course of women treated for early-stage breast cancer ( Figure 1 ). The baseline cohort was comprised of women with an age range of 45 to 75 years treated with BCS for stage I/II breast cancer. To advance time in our model, we used an annual cycle length. A more detailed description of the model is presented in the Supplementary Methods (available online). Key model parameters are presented in Table 1 .
Comparators and Model Structure
All women enter the model disease free, having received either IORT at the time of surgery or postoperative HF-WBI or CF-WBI. Similar to the ELIOT (12), our model assumed that 5% of all patients who received IORT received additional radiation using conventional fractionation of 2 Gy to a total dose of 50 Gy.
In the model, patients transition among mutually exclusive and collectively exhaustive health states descriptive of the clinical course after BCS. During each cycle, the baseline cohort of disease-free women could remain disease-free or else could suffer locoregional recurrence, distant metastasis, or death attributed to breast cancer or other unrelated causes (12) . Local and regional recurrence in women who received HF-WBI or CF-WBI could be addressed with salvage mastectomy followed by reconstruction. Women with local recurrence after IORT were assumed to have a 50% chance of salvage with lumpectomy and adjuvant whole breast irradiation (WBI) (17) . all women enter in a "disease-free" health state. As time progresses, women transition from one health state to another and acquire cost and utilities associated with that health state. Women at any stage may transition to death attributed to breast cancer or other unrelated causes. The model is structured over the time horizon of lifetime. CF-WBI ¼ conventionally fractionated whole breast irradiation; HF-WBI ¼ hypofractionated whole breast irradiation; IORT ¼ intraoperative radiation therapy.
Data Sources
Clinical Data Risks of local recurrence, distant metastases, and mortality following either IORT or WBI were derived from the ELIOT trial (Table 1 ; Supplementary Methods, available online). This trial randomly assigned 1305 women older than age 48 years with tumors less than 2.5 cm in diameter treated with breast conservation surgery (BSC) to either IORT or CF-WBI. IORT was delivered as a single dose of 21 Gy prescribed to the 90% depth using intraoperative electrons. CF-WBI was delivered to the whole breast to a dose of 50 Gy in 25 fractions, followed by a 10 Gy boost in five fractions. With a median follow-up of 5.8 years, the fiveyear locoregional recurrence rate was 5.4% for IORT vs 0.8% for the CF-WBI (P < .001) (12) . Locoregional recurrence risk (LRR), distant metastasis risk (DMR), and mortality outcomes were derived from the ELIOT rather than the TARGIT-A because the ELIOT had a longer follow-up, delivered a higher dose to the tumor bed, and utilized consistent external beam technique (ie, all patients received a boost). For our models, we also assumed that women who had both IORT and WBI had the same rate of LRR as women who had WBI alone (18, 19) .
For comparing HF-WBI and CF-WBI, we used 10-year follow-up data from two large randomized controlled trials that demonstrated equivalent LRR, DMR, and mortality between the two external beam therapies (6, 9, 20) . Risk of metastases after salvage mastectomy was derived from published sources (21, 22) .
Breast cancer mortality and other-cause mortality during the first five years after BCS were derived from the ELIOT (12) . After the first five years, we extrapolated age-specific breast cancer mortality risk and other-cause mortality risk and validated the trend in mortality by comparing it with the 15-year breast and all-cause mortality trend from a previously published meta-analysis (23) .
Costs
Direct medical care costs, including physician and hospital reimbursement for surgical procedures and respective radiation modalities, were obtained from the 2016 Medicare Physician Fee Schedule (24) and Outpatient Prospective Payment System (25) ( Table 1) . Estimates for indirect care, routine follow-up, and metastatic care costs were obtained from the literature and converted to 2016 US dollars using consumer price indices for medical care (26) (27) (28) (29) (24, 25) 57 (28 to 111) c IORT and lumpectomy (24, 25) 7461 (3730 to 14 922) c IORT followed by WBI (24, 25) 13 911 (6955 to 20 866) c HF-WBI (24, 25) 7814 (3907 to 15 628) c CF-WBI (24, 25) 10 464 (5232 to 15 696) c Salvage mastectomy and reconstruction (24, 25, 29) 13 116 (6558 to 19 674) c Salvage lumpectomy (24, 25) 2580 (1259 to 3778) c Indirect costs (IORT followed by CF-WBI) (26, 28) 1312 (656 to 2624) c Indirect costs (HF-WBI) (26, 28) 704 (352 to 1408) c Indirect costs (CF-WBI) (26, 28) 1548 (774 to 2322) c Routine disease-free follow-up care (annual) (27, 32) 1987 (994 to 3974) c First year of metastatic disease care (40) 37 708 (18 564 to 56 562) c Annual treatment of metastatic patients in remission (40) 8512 (4256 to 12 768) c Utilities Supplementary Table 2 (30) . In this trial, women age 40 years or older with pathologically confirmed early-stage breast cancer who underwent BCS were randomly assigned to treatment with either CF-WBI or HF-WBI and were followed over five years to assess quality of life (30) . We then used a mapping algorithm to convert the quality of life score into preference-based utilities. We used averages and standard deviations from the FACT-B subscales, which were available to us from personal communication. Longitudinal utilities after salvage mastectomy and reconstruction, salvage lumpectomy, and metastatic breast cancer were obtained from the published literature (31, 32) . In addition, the age-specific differential quality of life multipliers were obtained from Hanmer et al. (33) . Additional details and utilities are presented in Supplementary Methods and Supplementary Table 2 (available online).
Analysis
Cost-effectiveness Analysis To perform cost-effectiveness analysis, we followed the guidelines by the Second Panel on Cost-Effectiveness in Health and Medicine (34) . Base case outcomes were estimated for a cohort of women age 50 years who received BCS followed by IORT, HF-WBI, or CF-WBI. Outcomes were estimated assuming both US societal and health care sector perspectives as recommended (34) . Comparative assessment was performed by computing an incremental cost-effectiveness ratio (the ratio of difference in expected costs and expected QALYs associated with the alternative strategies). We used a lifetime horizon and discounted all future costs and QALYs using an annual discount rate of 3%.
For each perspective, we explored two scenarios wherein 1) radiation-associated disutility or side effects persist after year 5 and 2) radiation-associated disutility discontinues after year 5. These scenarios were utilized because radiation-associated quality of life beyond five years after treatment is not sufficiently described in the literature.
Sensitivity Analysis
To evaluate the robustness of the outcomes, we performed comprehensive sensitivity analysis. Deterministic (one-way and two-way) sensitivity analyses were conducted by varying model input parameters. In addition, decision uncertainty was evaluated using probabilistic sensitivity analysis and the outcomes were reported as probability of cost-effectiveness at US$50 000 per QALY and US$100 000 per QALY and costeffectiveness acceptability curves. Finally, we estimated costeffectiveness using model input parameters from the TARGIT-A clinical trial (11).
Model Validation
We performed comprehensive model validation as recommended by the Assessment of the Validation Status of HealthEconomic decision models (AdViSHE) (35) . First, we cross-validated our model by comparing model-predicted 10-year overall survival for women age 55 years to the survival estimated in a previously published cost-effectiveness analysis (details are presented in the Supplementary Methods, available online) (36) . Second, we independently validated our model by comparing five-year and 10-year survival in women age 50 years by comparing predicted survival by a web-based prediction tool: Predictonline! (Supplementary Table 3 , available online) (37) . We also compared model-predicted five-year and 10-year local recurrence rates to the empirical data not used to build the model. (Supplementary Table 4 , available online). The accuracy 
Results
Cost-effectiveness Analysis
The results of base case cost-effectiveness analysis are presented in Table 2 . Notably, HF-WBI dominated CF-WBI in all scenarios because CF-WBI was associated with increased costs and decreased QALYs regardless of model assumptions. HF-WBI was more cost-effective than IORT in most scenarios. In the base case using a societal perspective and assuming that radiation-associated disutility persists beyond five years, we found that the ICER associated with HF-WBI compared with IORT was $17 024 per QALY ( Table 2 ). The probability that HF-WBI was cost-effective was 75% and 80% at willingness-to-pay thresholds of $50 000 per QALY and $100 000 per QALY, respectively. Under the alternative scenario where radiationassociated disutility was assumed to discontinue after five years, we found that the ICER for HF-WBI compared with IORT was $11 461 per QALY. The probability that HF-WBI was costeffective was higher than the base case, increasing to 76% and 83% at $50 000 per QALY and $100 000 per QALY.
When the outcomes comparing HF-WBI and IORT were estimated using a health care sector perspective instead of a societal perspective, we found that the ICER again was in favor of HF-WBI: Under the scenarios that assume that radiation-associated disutility persists or discontinues beyond five years after treatment, the ICERs were $14 886 per QALY and $10 022 per QALY, respectively (Table 2) .
Sensitivity Analysis
The top five model parameters in terms of costs and probabilities in the order of their impact on the ICER, estimated using *Conventional-fractionated whole breast irradiation was dominated throughout the analysis. CF-WBI ¼ conventional-fractionated whole breast irradiation; HF-WBI ¼ hypofractionated whole breast irradiation; ICER ¼ incremental cost-effectiveness ratio; IORT ¼ intraoperative radiation therapy; QALY ¼ quality-adjusted life-year. †The ICER comparing only undominated strategies (ie, IORT and HF-WBI) was reported.
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one-way sensitivity analysis, are presented in the form of a tornado diagram (Figure 2 ). We found that the ICER was sensitive to the treatment cost of HF-WBI and IORT (Figure 2A ). The ICER was also sensitive to the probability of metastasis after treatment ( Figure 2B ). However, under no alternative scenario, the ICER exceeded the threshold of $100 000 per QALY. In the two-way sensitivity analysis, we found that the ICER was sensitive to the linear combination of the probability of metastasis after HF-WBI and IORT; when base case parameters were used, then HF-WBI was most cost-effective. The region of costeffectiveness under the possible combination of probability of metastasis after HF-WBI and IORT is presented in Supplementary  Figure 2 (available online). We also found that the ICER was sensitive to the linear combination of cost of HF-WBI and age, and cost of IORT and age (Supplementary Figures 3 and 4, available online) .
Additional sensitivity analyses are presented in Table 3 . Notably, the ICER for HF-WBI compared with IORT increases with older age. However, under no sensitivity analysis did the ICER exceed the willingness-to-pay threshold of $100 000 per QALY.
Using probabilistic sensitivity analysis, we estimated that HF-WBI was the most cost-effective strategy at the willingnessto-pay threshold of $10 000 per QALY or higher for the base case population ( Figure 3A) . We then found that the probability that HF-WBI is cost-effective decreases with increase in age across the willingness-to-pay threshold ( Figure 3B) . Finally, when model inputs (ie, local and regional recurrence, risk of metastasis, and mortality) from TARGIT-A were used (Supplementary Table 5 , available online), we found that the incremental costeffectiveness ratio further decreased (ie, the ICER was $6277/ QALY) (Supplementary Table 6 , available online).
Discussion
Individual patients have more recently been willing to adopt the posture of a discerning consumer-searching for high quality at relatively low cost-because of their increased exposure to the costs of care secondary to rising copayments and the proliferation of high-deductible insurance plans. Likewise, an urgent goal for health care purchasers and policy-makers is to incentivize interventions that are clinically effective but also entail sustainable costs for managing whole populations of patients. This focus on value for selecting treatment is especially apt for clinical scenarios with three features: The indication for treatment is highly prevalent, several treatment options exist with similar clinical efficacy, and the costs and toxicity profiles vary across the treatment options.
In the oncology landscape, this constellation of features is represented well by treatment selection among the adjuvant radiotherapy options available after breast conservation surgery. To identify which among the treatment options entailed the best value, we utilized prospective outcomes from major randomized clinical trials to compare the cost-effectiveness of CF-WBI, HF-WBI, and IORT. We found that HF-WBI is cost-effective compared with IORT and CF-WBI from both a societal and health care sector perspective. Of note, because our model was based on data from well-designed clinical trials, few supplementary assumptions were needed to complete the analysis. The one major modeling assumption for which long-term data was unavailable was whether radiation-associated disutility persisted or ceased beyond five years of follow-up. We found that under either circumstance, the ICER for HF-WBI remained well below the acceptable willingness-to-pay threshold of $100 000 per QALY. In other words, HF-WBI was the most costeffective option under all modeling scenarios.
The sensitivity analyses highlight an important caveat to the interpretation of our results. Namely, the comparative value of hypofractionated radiotherapy is contingent on the costs of therapy as well as on relative recurrence rates. The costs used in our analysis were based on current reimbursement rates, but it is intuitive that a lower price point for intraoperative radiotherapy or higher price of hypofractionated radiotherapy could tilt the cost-effectiveness calculation in favor of IORT, particularly in older women. Similarly, our model based IORT clinical outcomes on the ELIOT trial, which demonstrated modestly inferior tumor control compared with WBI. However, the ELIOT trial allowed participation of patients who were at higher risk for recurrence than patients deemed "suit- A) The panel provides a probability that conventionally fractionated whole breast irradiation, hypofractionated whole breast irradiation (HF-WBI), or intraoperative radiation therapy is cost-effective for a range of willingness-to-pay thresholds that a decision maker may consider acceptable. B) The panel provides a probability that the most optimal strategy (ie, HF-WBI) is cost-effective by patient age for a range of willingness-to-pay thresholds that a decision maker may consider acceptable.
CF-WBI ¼ conventionally fractionated whole breast irradiation; HF-WBI ¼ hypofractionated whole breast irradiation; IORT ¼ intraoperative radiation therapy; QALY ¼ quality-adjusted life-year; WTP ¼ willingness to pay.
Orecchia and colleagues, the 23% of ELIOT patients who did fit the suitability criteria were estimated to have a five-year local recurrence risk of only 1.5% (38, 39) . This suggests that for properly selected low-risk patients for whom there is minimal anticipation of downstream costs for treating recurrences, a single intraoperative radiation session may turn out to be costeffective compared with HF-WBI. However, even if IORT costs are modified such that this technique becomes the more costeffective option, IORT requires special equipment and technical competencies, which will need to be overcome for more widespread adoption.
Despite the expectation that CF-WBI would be dominated by HF-WBI under all alternative scenarios as HF-WBI is less costly, equally effective, and probably less toxic than CF-WBI, we included CF-WBI as a comparator. This is because the uptake of HF-WBI in the United States still remains low and majority of the women are still undergoing CF-WBI (8) . Therefore, the analysis was conducted to address the following question: What is the cost-effectiveness of replacing existing practice (CF-WBI) with a new intervention (IORT) or relevant alternative (HF-WBI)?
An important limitation of our study revolves around uncertainty surrounding quality of life assumptions. As in other studies, quality of life is a subjective outcome that varies from individual to individual and greatly depends on the survey instruments. Because the external beam radiation arm utilized CF-WBI, it is likely that the difference in utility between IORT and HF-WBI would not be as pronounced. However, it is worthwhile to point out that the impact of this change on our model would actually make our primary conclusion, that HF-WBI is more cost-effective than IORT, stronger.
In conclusion, in selecting among HF-WBI, CF-WBI, and IORT for adjuvant radiotherapy after breast conservation surgery, HF-WBI is the most cost-effective option. At a lower price point, IORT could become a convenient, high-value intervention for older patients at low risk of requiring salvage therapy. 
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